<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02972866</url>
  </required_header>
  <id_info>
    <org_study_id>EF148</org_study_id>
    <nct_id>NCT02972866</nct_id>
  </id_info>
  <brief_title>Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis</brief_title>
  <acronym>RINEX32</acronym>
  <official_title>Phase III, Multicenter, Randomized, Simple-blinded, Paralel Groups to Evaluate Non Inferiority of Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Persistent Rhinitis Moderate to Severe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate non inferiority of Eurofarma budesonide nasal spary x referral
      Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients
      will receive Astrazeneca medication. There is no placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Budesonide is a medicine already very used and registered about 20 years. Eurofarma has the
      intention to collect more data about safety and efficacy and present them to local authority.

      This study was draw to treat patients with persisntent rhinits moderate to severe in sites
      localted locally in Brasil.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate non inferiority of Noex comparable with referral product Budecort Aqua in the treatment of rinithis moderate to severe during 4 weeks of treatment.</measure>
    <time_frame>28 days</time_frame>
    <description>The questionnaire Nasal Index Score (NIS) will be used to check intensity of symptons and patient will answer this questionnaire daily at home.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">456</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <arm_group>
    <arm_group_label>Noex 32mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Noex/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.
Tretament of 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budecort Aqua 32 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budecort Aqua/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.
Tretament of 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Suspention to nasal use, 2 atomization in each nostril during the morning and at night.</description>
    <arm_group_label>Noex 32mcg</arm_group_label>
    <arm_group_label>Budecort Aqua 32 mcg</arm_group_label>
    <other_name>Noex 32mcg</other_name>
    <other_name>Budecort Aqua 32mcg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 12.

          2. History of alergic persistent rhinitis moderate to severe at least 2 years.

          3. Proved alergic using PRICK or RAST test.

          4. Nasal symptoms (NIS) &gt; 3 and nasal obstruction &gt;1.

          5. Indication of nasal corticorteroids use..

          6. Washout of nasal corticorteroids for 14 days.

          7. ICF.

        Exclusion Criteria:

          1. Other types of rhinitis;

          2. Asthma non controled

          3. Use of oral/injectable corticoids 30 days before screening.

          4. patients not eligible to complete diaries.

          5. patients with alergy to any substance of medicines.

          6. non controlled desease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro Acir Crippa Junior</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergisa pesquisa dermato-cosmética Ltda.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Dumont</last_name>
    <phone>+5519 3789-8600</phone>
    <email>alexandra@grupoinvestiga.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Allergisa pesquisa dermato-cosmética ltda</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauro Acir Crippa Junior, MD</last_name>
      <phone>+5519 3789-8600</phone>
      <email>alexandra@grupoinvestiga.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2016</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided, but could be shared upon investigator's request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

